Advances in Clinical Medicine
Vol. 12  No. 04 ( 2022 ), Article ID: 50714 , 7 pages
10.12677/ACM.2022.124463

胃切除术后胆囊结石形成机制及防治的 研究进展

易付杰1,范宏丹2,龚建平2*

1重庆城口县人民医院外科,重庆

2重庆医科大学附属第二医院肝胆外科,重庆

收稿日期:2022年3月22日;录用日期:2022年4月16日;发布日期:2022年4月25日

摘要

胃切除术作为治疗胃癌及部分严重消化性溃疡的主要外科治疗手段,在近些年得到了长足的发展,而随着肥胖症及其相关疾病的逐年上升,胃切除术也更多地应用于减重代谢手术中。胆囊结石是胃切除术后远期并发症之一,随着术后生存期的延长及人们对生活质量要求的提高,胃切除术后胆囊结石的相关问题日趋得到临床医生的重视。近年来其相关机制及危险因素逐渐明朗,但针对其防治措施,在学界仍存在着一定争议。本文现就胃切除术后胆囊结石的形成机制、危险因素及防治策略等方面的研究进展作一综述。

关键词

胃切除术,胆囊结石,并发症,研究进展

Research Progress on Mechanism, Prevention and Treatment of Gallstone Formation after Gastrectomy

Fujie Yi1, Hongdan Fan2, Jianping Gong2*

1Department of Surgery, Cheng Kou People’s Hospital, Chongqing

2Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Received: Mar. 22nd, 2022; accepted: Apr. 16th, 2022; published: Apr. 25th, 2022

ABSTRACT

As the main surgical treatment for gastric cancer and some severe peptic ulcer, gastrectomy has made great progress in recent years. With the increase of obesity and related diseases year by year, gastrectomy is also more used in bariatric surgery. Gallstone formation is one of the late complications after gastrectomy. With the extension of postoperative survival and the improvement of people’s requirements for quality of life, clinicians pay more and more attention to the related problems of post-gastrectomy gallstones. In recent years, its related mechanisms and risk factors have become increasingly clear, but there are still some disputes in the academic circles about its prevention and control measures. This paper reviews the research progress of post-gastrectomy gallstones from the aspects of formation mechanism, risk factors and prevention and treatment strategies.

Keywords:Gastrectomy, Gallstone, Complication, Research Progress

Copyright © 2022 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

1. 前言

胆囊结石是胃切除术后的远期并发症,研究报道,在胃癌患者术后胆囊结石发病率较正常人群明显升高 [1],而在减重手术后胆囊结石发病率亦高于正常人群发病率 [2]。迷走神经损伤及胃肠激素改变是胃切除术后胆囊结石形成的主要两大机制,而术中胃切除范围、消化道重建方式及淋巴结清扫范围等则是胃切除术后胆囊结石形成的危险因素,但其深层机制及相关危险因素仍有待进一步研究。因术后胆囊结石发病率升高导致二次手术率升高,是否术中同期行预防性胆囊切除术仍是一大争议性热点话题,而药物防治与手术防治的对比效果在学界仍未达到统一意见。

2. 胃切除术后胆囊结石形成机制

2.1. 神经损伤

副交感神经系统对胃肠道动力兼具有兴奋和抑制双重作用,其中迷走神经扮演了关键角。胃迷走神经前干分出肝支和胃前支,后干分出腹腔支和胃后支,其中肝支随固有动脉走形,参与形成肝从,对肝脏分泌及胆囊收缩起着重要的调节作用 [3]。Wang等 [4] 研究显示,迷走神经损伤是胆囊结石形成的独立危险因素,在胃癌患者行腹腔镜远端胃切除术和保留幽门的胃切除术的病例中,术中保留迷走神经肝支可以减少术后胆囊结石的发生。同时,迷走神经还参与调节Oddi括约肌的运动从而控制胆汁排泄,迷走神经损伤后导致Oddi括约肌功能障碍,影响胆汁从胆总管排入肠道,导致胆汁淤积及胆道结石形成。Nabae等 [5] 的动物试验通过迷走神经切断术前后的十二指肠插管逆行输注测压记录Oddi括约肌运动性,研究发现,离断迷走神经后Oddi括约肌循环运动和胃十二指肠迁移运动出现紊乱,这将部分解释胃切除术后或迷走神经切断术后胆囊结石的成因。综上,迷走神经及其分支损伤在胃切除术后胆囊结石中有着重要的意义。

2.2. 胃肠激素改变

胃肠激素在胃肠运动及营养物质的吸收和代谢有重要调节作用,胃切除术后胃肠激素紊乱是术后胆囊结石形成的重要原因之一。胆囊收缩素(cholecystokinin, CCK)在主要通过刺激胆囊收缩与Oddi括约肌松弛促进胆汁排泄。胃切除术及消化道重建后,CCK水平下降,导致胆囊排空障碍及胆汁排泄异常,从而促进术后胆囊结石形成。同时,CCK减少可以影响肠肝循环,胆汁中胆固醇与胆盐比例失衡,胆固醇结晶析出易导致胆固醇结石。动物试验表明 [6],靶向破坏小鼠体内CCK或CCK-1受体(CCK-1R)基因导致胆囊排空和胆道胆固醇代谢障碍,同时促进肠道对胆固醇的吸收,显著增加了胆固醇胆结石的形成。但也有相关研究提示甚至在减重手术后CCK水平上升 [7]。此外,胃切除术后促胃液素、胰高血糖素、胃动素、血管活性肠肽、生长抑素等胃肠激素的改变均可能会导致术后胆囊结石形成。

3. 胃切除术后胆囊结石形成危险因素

3.1. 与手术相关危险因素

3.1.1. 胃切除范围

前文已述,神经损伤及胃肠激素改变是胃切除术后胆囊结石形成的两大主流学说,因此不同的胃切除范围伴随着不同神经损伤及胃肠激素改变,对术后胃肠运动及营养物质的吸收及代谢的影响程度不同,对术后胆囊结石形成的易感性也不同。在胃癌患者中,根据肿瘤位置不同,常见切除方式包括近端胃切除术、远端胃切除术和全胃切除术,其中根据是否保留幽门可将远端胃切除术分为保留幽门远端胃切除术和不保留幽门胃切除术。在韩国 [8],一项全国性回顾性队列研究结果显示,不同胃切除方式的胃癌患者术后胆囊结石发生率不同,在术后5年随访期间,全胃切除、近端胃切除、远端胃切除及保留幽门远端胃切除术后胆囊结石发病率分别为6.6%、5.4%、4.8%、4.0%,差异有统计学意义(P < 0.05),其中全胃切除是术后胆囊结石形成的独立危险因素。另一项比较腹腔镜辅助幽门保留胃切除术(laparoscopic-assisted pylorus-preserving gastrectomy, LAPPG)与腹腔镜辅助远端胃切除术(laparoscopy-assisted distal gastrectomy, LADG)治疗胃中部三分之一的早期胃癌的回顾性研究 [9],结果发现对于胃中部的早期胃癌,LAPPG在营养优势和胆囊结石发病率较低方面可被视为比LADG更好的治疗选择。相关meta分析 [10] 显示,在治疗早期胃中部癌中,保留幽门胃切除较不保留幽门胃切除术后胆囊结石发病率更低,且术后整体并发症和长期生存率相当。

3.1.2. 消化道重建方式

在胃肿瘤术中消化道重建方式多种多样,总体上分为生理性及非生理性重建,其中生理性重建以Billroth I式吻合术和空肠间置术为主,非生理性重建以Billroth II式和Roux-en-Y吻合术为主。而在代谢减重手术中,以胃袖状切除术(sleeve gastrectomy, SG)及Roux-en-Y胃旁路术(Roux-en-Y gastric bypass, RYGB)为最主要的两种术式。最新的回顾性研究 [11] 发现,在行腹腔镜远端胃切除术或腹腔镜全胃切除术后胆囊结石发病率明显升高,且Roux-en-Y吻合术是腹腔镜胃切除术后胆囊结石形成的重要危险因素。Paik等 [12] 的回顾性研究分析了胃切除术后胆囊结石形成的危险因素,发现行Billroth I式吻合术的术后胆囊结石发病率低于Billroth II式吻合术,且Billroth II式吻合术是胃切除术后形成胆囊结石的危险因素。Chen等 [13] 通过meta分析得出非生理性消化道重建与远端胃切除术后胆囊结石发生风险增加显著相关。分析原因,可能是因为非生理性消化道重建后,十二指肠及上段空肠缺少食物刺激导致CCK分泌不足,从而导致胆囊排空和胆道胆固醇代谢障碍。在减重手术中RYGB重建消化道,Sneineh等 [14] 通过回顾性研究发现在中位随访时间12个月内,6.2%的患者在减重术后出现有症状的胆囊结石,其中RYGB术后有症状胆囊结石发病率高达14.5%,结果表明,RYGB术后胆囊结石及症状性胆囊疾病风险较高。但也有相关回顾性队列研究 [15] 发现在腹腔镜袖状胃切除术(laparoscopic sleeve gastrectomy, LSG)和腹腔镜Roux-en-Y胃旁路术(laparoscopic Roux-en-Y gastric bypass, LRYGB)后有症状的胆石症的发生率无明显差异,而体质量下降过快是胆囊结石形成的主要危险因素。

3.1.3. 淋巴结清扫范围

术中清扫肿瘤周围淋巴结可以达到根治切除从而获得更好的预后,但术中淋巴结清扫不可避免伴随着神经损伤,故胃切除术伴随淋巴结清扫术后胆囊结石发病率较单纯胃切除术高,而淋巴结清扫范围是胃切除术后胆囊结石形成的重要危险因素 [16]。在清扫肝十二指肠韧带的No. 12组淋巴结时,损伤支配胆囊的迷走神经肝支是胆囊结石形成的重要原因。Akatsu等 [17] 的回顾性研究结果显示在胃癌根治术中D2淋巴结清扫后胆囊结石发病率显著高于D1淋巴结清扫组(17.8% vs. 9.4%, p = 0.001),且发生时间更早,需二次手术者更多。D2 + 淋巴结清扫术被认为可以改善胃癌患者长期生存率,但术中分离肝十二指肠韧带时不可避免会破坏更多的交感及副交感神经,研究表明D2 + 淋巴结清扫术是术后胆囊结石形成的重要危险因素 [16]。以上研究表明,胃切除术伴随淋巴结清扫术与胆囊结石的发生密切相关,而随着清扫范围的扩大,神经损伤的程度可随之扩大,导致淋巴结清扫术后胆囊结石的易感性增加。

3.2. 其他危险因素

胃切除术后胆囊结石形成除上诉与手术相关的危险因素外,还可能与男性、年龄较大、糖尿病、体重下降过快等多种因素相关。且手术本身可能的造成腹腔组织水肿及粘连影响胆汁排泄,术后肠道及胆道感染风险增加,均有可能导致胆囊结石形成。此外,研究发现ApoB Xba I等位基因是根治性胃切除术后除胆囊动力障碍外胆囊结石形成的另一危险因素 [18]。

4. 胃切除术后胆囊结石防治策略

4.1. 胃切除术后胆囊结石的预防

前文已述,与手术相关的危险因素中,全胃切除术、不保留幽门的胃切除术、非生理性消化道重建以及扩大淋巴结清扫区域可增加胃切除术后胆囊结石形成的风险,因此,在能达到理想手术目的的前提下,尽可能选择较为合适的手术方式来减少术后胆囊结石的发生。同时术中操作仔细,尽量避免不必要的神经血管损伤亦可降低术后胆囊结石的发生。另外术后尽早进行肠内营养、减少胆固醇的摄入、定期行腹部超声检查等在术后胆囊结石的预防和早期发现中有着重要意义。

熊去氧胆酸(ursodeoxycholic acid, UDCA)是一种多功能亲水性胆汁酸,可降低胆汁中胆固醇及胆固醇脂,具有利胆作用。在韩国 [19],一项多中心、随机、双盲、安慰剂对照临床试验旨在研究UDCA预防胃癌患者胃切除术后胆囊结石形成的疗效和安全性,研究纳入已接受全胃切除术、远端胃切除术或近端胃切除术的成人胃癌患者,按1:1:1随机分配,每天接受300 mg UDCA、600 mg UDCA或安慰剂,持续52周,结果发现12个月内胆囊结石的发病率为300 mg组5.3%,600 mg组4.3%,安慰剂组16.7%,研究表明UDCA给药12个月显着降低了胃癌胃切除术后胆结石的发生率,UDCA给药可防止胃癌患者胃切除术后胆囊结石的形成。同样对于减重代谢手术,多项研究 [20] [21] [22] 显示在袖状胃切除术或胃旁路术后,持续口服熊去氧胆酸可以有效降低术后胆囊结石发生率。Fearon等 [23] 的meta分析结果显示,UDCA可显著降低减重手术后无症状和有症状胆囊结石发生的风险,无论何种手术类型,600 mg/天的剂量均可以改善依从性并获得更好的预后,UDCA应被视为减中手术后标准术后护理的一部分。但也有最新相关研究 [24] 显示,UDCA预防治疗并未显著降低所有患者减肥手术后有症状胆囊结石疾病的发生率,在RYGB术后UDCA治疗减少了有症状的胆囊结石疾病的发生,但需要进一步的研究来评估SG术后熊去氧胆酸的疗效。

胃切除术后胆囊结石发病率显著升高,导致二次手术率增高及二次手术难度加大,胃切除术中同期行预防性胆囊切除术(preventive cholecystectomy, PC)可以从根本解决术后胆囊结石的形成,但是否选择术中同期行PC在学界仍存在一定争论。Bencini等 [25] 的研究显示,胃切除术中同期行PC对患者的自然病程没有显著影响。同样的,Allatif等 [26] 的回顾性研究结果发现,减肥手术(LSG或LRYGB)期间接受了伴随的胆囊切除术与术中未行胆囊切除术相比,增加了手术时长,但在住院时间及并发症方面都没有显著差异。故对于术前合并胆囊结石尤其是伴随症状的患者,术中同期行PC是必要且安全可行的。而对于术前无胆囊结石的胃切除患者,关于术中是否同期行PC,不乏支持者 [1] 与反对者 [25]。笔者认为,对于此类患者,如术前评估发现其伴有明确或多项术后胆囊结石形成危险因素,在能达到理想手术目的且确保术中安全的情况下可行PC,而对于那些不伴有危险因素的患者,应视情况谨慎行PC,未行PC的患者在术后应尽早使用UDCA等药物及调整饮食生活习惯以预防胆囊结石的发生。

4.2. 胃切除术后胆囊结石的治疗

针对胃切除术后胆囊结石的治疗以外科手术为主,当患者胆囊结石处于静止期且合并其他严重内科疾病而存在手术禁忌者,可行保守治疗。随着腹腔镜以及内镜技术的成熟与发展,微创外科理念与技术的提高,腹腔镜胆囊切除术(laparoscopic cholecystectomy, LC)是目前针对胆囊良性疾病最主要的手术方式,此外内镜下逆行胰胆管造影术、内镜下十二指肠乳头括约肌切开术,经皮经肝穿刺术在治疗胆囊结石及胆总管结石方面也发挥着重要的作用。Harino [27] 等的前瞻性研究证实,虽然相较于无腹部手术史的患者,有既往上腹部手术史在中转开腹率、手术时长、相关并发症方面显著升高,但对于有上腹部手术史的患者来说,LC仍是一种安全有效的治疗方法。虽然胃切除手术史会增加LC术中难度及术后康复时间,但对比与传统开服手术,LC目前仍是首选的手术方式。近年来,机器人辅助手术快速发展,机器人辅助胆囊切除术也得到了多方面的开展,Han等 [28] 的meta分析比较了机器人辅助与传统腹腔镜胆囊切除术治疗良性胆囊疾病疗效,与传统LC相比,机器人辅助腹腔镜下胆囊切除术的手术时间延长,切口疝发生率降低,而在术中及术后并发症、30天再入院率、住院时间、失血量等方面,两者之间均无统计学差(均P > 0.05),说明在胆囊良性疾病的治疗上,机器人辅助腹腔镜下胆囊切除术并不比传统LC有优势。但对于胃切除术后胆囊结石尤其是伴随腹腔粘连等情况导致手术困难的这类患者,机器人辅助胆囊切除术是否更具有优势仍有待进一步的研究。

5. 总结与展望

综上所诉,神经损伤及胃肠激素改变是胃切除术后胆囊结石形成的两大主要机制,而胃切除范围、消化道重建方式、淋巴结清扫范围是其主要的危险因素,但深层次的发病机制及危险因素仍有待进一步的研究。防治方面,UDCA可有效预防胃切除术后胆囊结石的形成,其安全性也得到多项研究的支持,而针对术中同期行预防性胆囊切除的安全性及必要性仍是学界一大争议性话题,在未来,需要更多的临床研究和相关数据佐证。LC仍是胃切除后胆囊结石治疗的主要方式,随着现代外科的进展,新兴的技术及医疗器械的升级可以更好地辅助完成疾病的治疗。总之,随着胃切除术后患者生存期的延长及对生活质量要求的提高,胆囊结石这一术后并发症已得到人们的重视,未来也会有更多、更深入的基础研究及临床试验。

文章引用

易付杰,范宏丹,龚建平. 胃切除术后胆囊结石形成机制及防治的研究进展
Research Progress on Mechanism, Prevention and Treatment of Gallstone Formation after Gastrectomy[J]. 临床医学进展, 2022, 12(04): 3214-3220. https://doi.org/10.12677/ACM.2022.124463

参考文献

  1. 1. Liang, T.J., Liu, S.I., Chen, Y.C., Chang, P.M., Huang, W.C., Chang, H.T., et al. (2017) Analysis of Gallstone Disease after Gastric Cancer Surgery. Gastric Cancer, 20, 895-903. https://doi.org/10.1007/s10120-017-0698-5

  2. 2. Anveden, A., Peltonen, M., Naslund, I., Torgerson, J. and Carlsson, L.M.S. (2020) Long-Term Incidence of Gallstone Disease after Bariatric Surgery: Results from the Nonran-domized Controlled Swedish Obese Subjects Study. Surgery for Obesity and Related Diseases, 16, 1474-1482. https://doi.org/10.1016/j.soard.2020.05.025

  3. 3. Browning, K.N. and Travagli, R.A. (2014) Central Nervous System Control of Gastrointestinal Motility and Secretion and Modulation of Gastrointestinal Functions. Comprehensive Physiology, 4, 1339-1368. https://doi.org/10.1002/cphy.c130055

  4. 4. Wang, C.J., Kong, S.H., Park, J.H., Choi, J.H., Park, S.H., Zhu, C.C., et al. (2021) Preservation of Hepatic Branch of the Vagus Nerve Reduces the Risk of Gallstone Formation after Gastrectomy. Gastric Cancer, 24, 232-244. https://doi.org/10.1007/s10120-020-01106-z

  5. 5. Nabae, T., Yokohata, K., Otsuka, T., Inoue, K., Yamaguchi, K., Chijiiwa, K., et al. (2002) Effect of Truncal Vagotomy on Sphincter of Oddi Cyclic Motility in Conscious Dogs. Annals of Surgery, 236, 98-104. https://doi.org/10.1097/00000658-200207000-00015

  6. 6. Wang, H.H., Portincasa, P. and Wang, D.Q. (2019) Update on the Molecular Mechanisms Underlying the Effect of Cholecystokinin and Cholecystokinin-1 Receptor on the Formation of Cholesterol Gallstones. Current Medicinal Chemistry, 26, 3407-3423. https://doi.org/10.2174/0929867324666170619104801

  7. 7. Svane, M.S., Bojsen-Moller, K.N., Martinussen, C., Dirksen, C., Madsen, J.L., Reitelseder, S., et al. (2019) Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion after Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. Gastroenterology, 156, 1627-1641. https://doi.org/10.1053/j.gastro.2019.01.262

  8. 8. Seo, G.H., Lim, C.S. and Chai, Y.J. (2018) Incidence of Gall-stones after Gastric Resection for Gastric Cancer: A Nationwide Claims-Based Study. Annals of Surgical Treatment and Research, 95, 87-93.

  9. 9. Suh, Y.S., Han, D.S., Kong, S.H., Kwon, S., Shin, C.I., Kim, W.H., et al. (2014) Lap-aroscopy-Assisted Pylorus-Preserving Gastrectomy Is Better than Laparoscopy-Assisted Distal Gastrectomy for Mid-dle-Third Early Gastric Cancer. Annals of Surgery, 259, 485-493. https://doi.org/10.1097/SLA.0b013e318294d142

  10. 10. 杜耀, 李卫平, 熊辉, 等. 保留幽门胃切除术治疗早期胃中部癌有效性和安全性的Meta分析[J]. 中华胃肠外科杂志, 2020, 23(11): 1088-1096.

  11. 11. Fujita, S., Kimata, M., Matsumoto, K., Sasakura, Y., Terauchi, T., Furukawa, J., et al. (2022) Important Risk Factors for Gallstones after Laparoscopic Gastrectomy: A Retrospective Study. BMC Surgery, 22, Article No. 5. https://doi.org/10.1186/s12893-021-01458-y

  12. 12. Paik, K.H., Lee, J.C., Kim, H.W., Kang, J., Lee, Y.S., Hwang, J.H., et al. (2016) Risk Factors for Gallstone Formation in Resected Gastric Cancer Patients. Medicine (Baltimore), 95, e3157. https://doi.org/10.1097/MD.0000000000003157

  13. 13. Chen, Y. and Li, Y. (2017) Related Factors of Post-operative Gallstone Formation after Distal Gastrectomy: A Meta-Analysis. Indian Journal of Cancer, 54, 43-46. https://doi.org/10.4103/ijc.IJC_91_17

  14. 14. Sneineh, M.A., Harel, L., Elnasasra, A., Razin, H., Rotmensh, A., Moscovici, S., et al. (2020) Increased Incidence of Symptomatic Cholelithiasis after Bariatric Roux-en-Y Gastric Bypass and Previous Bariatric Surgery: A Single Center Experience. Obesity Surgery, 30, 846-850. https://doi.org/10.1007/s11695-019-04366-6

  15. 15. Golzarand, M., Toolabi, K., Parsaei, R. and Eskandari Delfan, S. (2021) Incidence of Symptomatic Cholelithiasis Following Laparoscopic Roux-en-Y Gastric Bypass Is Comparable to Laparoscopic Sleeve Gastrectomy: A Cohort Study. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-021-07306-6

  16. 16. Fukagawa, T., Katai, H., Saka, M., Morita, S., Sano, T. and Sasako, M. (2009) Gallstone Formation after Gastric Cancer Surgery. Journal of Gastrointestinal Surgery, 13, 886-889. https://doi.org/10.1007/s11605-009-0832-8

  17. 17. Akatsu, T., Yoshida, M., Kubota, T., Shimazu, M., Ueda, M., Otani, Y., et al. (2005) Gallstone Disease after Extended (D2) Lymph Node Dissection for Gastric Cancer. World Journal of Surgery, 29, 182-186. https://doi.org/10.1007/s00268-004-7482-5

  18. 18. Liu, F.L., Lu, W.B. and Niu, W.X. (2010) XbaI Polymorphisms of Apolipoprotein B Gene: Another Risk Factor of Gallstone Formation after Radical Gastrectomy. World Journal of Gastroenterology, 16, 2549-2553. https://doi.org/10.3748/wjg.v16.i20.2549

  19. 19. Lee, S.H., Jang, D.K., Yoo, M.W., Hwang, S.H., Ryu, S.Y., Kwon, O.K., et al. (2020) Efficacy and Safety of Ursodeoxycholic Acid for the Prevention of Gallstone Formation after Gastrectomy in Patients with Gastric Cancer: The PEGASUS-D Randomized Clinical Trial. JAMA Surgery, 155, 703-711. https://doi.org/10.1001/jamasurg.2020.1501

  20. 20. Della, P.A., Lange, J., Hilbert, J., Archid, R., Königsrainer, A., Quante, M., et al. (2019) Ursodeoxycholic Acid for 6 Months After Bariatric Surgery Is Impacting Gallstone Associated Morbidity in Patients with Preoperative Asymptomatic Gallstones. Obesity Surgery, 29, 1216-1221. https://doi.org/10.1007/s11695-018-03651-0

  21. 21. Salman, M.A., Salman, A., Mohamed, U.S., Hussein, A.M., Ameen, M.A. and Omar, H.S.E., et al. (2022) Ursodeoxycholic Acid for the Prevention of Gall Stones after Laparoscopic Sleeve Gastrectomy: A Prospective Controlled Study. Surgical Endoscopy. https://doi.org/10.1007/s00464-021-08980-3

  22. 22. Machado, F., Castro, F.H., Babadopulos, R., Rocha, H.A.L., Rocha, J.L.C., Moraes Filho, M.O. (2019) Ursodeoxycholic Acid in the Prevention of Gallstones in Patients Subjected to Roux-en-Y Gastric Bypass1. Acta Cirúrgica Brasileira, 34, e631258487. https://doi.org/10.1590/s0102-865020190010000009

  23. 23. Fearon, N.M., Kearns, E.C., Kennedy, C.A., Conneely, J.B. and Heneghan, H.M. (2022) The Impact of Ursodeoxycholic Acid on Gallstone Disease after Bariatric Surgery: A Meta-Analysis of Randomized Control Trials. Surgery for Obesity and Related Diseases, 18, 77-84. https://doi.org/10.1016/j.soard.2021.10.004

  24. 24. Haal, S., Guman, M., Boerlage, T., Acherman, Y.I.Z., de Brauw, L.M., Bruin, S., et al. (2021) Ursodeoxycholic Acid for the Prevention of Symptomatic Gallstone Disease after Bariatric Surgery (UPGRADE): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Superiority Trial. The Lancet Gastroenterology and Hepatology, 6, 993-1001. https://doi.org/10.1016/S2468-1253(21)00301-0

  25. 25. Bencini, L., Marchet, A., Alfieri, S., Rosa, F., Verlato, G., Marrelli, D., et al. (2019) The Cholegas Trial: Long-Term Results of Prophylactic Cholecystectomy during Gastrectomy for Cancer—A Randomized-Controlled Trial. Gastric Cancer, 22, 632-639. https://doi.org/10.1007/s10120-018-0879-x

  26. 26. Allatif, R.E.A., Mannaerts, G.H.H., Al Afari, H.S.T., Hammo, A.N., Al Blooshi, M.S., Bekdache, O.A., et al. (2021) Concomitant Cholecystectomy for Asymptomatic Gallstones in Bariatric Surgery-Safety Profile and Feasibility in a Large Tertiary Referral Bariatric Center. Obesity Surgery, 32, 295-301. https://doi.org/10.1007/s11695-021-05798-9

  27. 27. Lee, D.H., Park, Y.H., Kwon, O.S. and Kim, D. (2022) Laparoscopic Cholecystectomy in Patients with Previous Upper Midline Abdominal Surgery: Comparison of Laparo-scopic Cholecystectomy after Gastric Surgery and Non-Gastric Surgery Using Propensity Score Matching. Surgical Endoscopy, 36, 1424-1432. https://doi.org/10.1007/s00464-021-08427-9

  28. 28. Han, C., Shan, X., Yao, L., Yan, P., Li, M., Hu, L., et al. (2018) Robotic-Assisted versus Laparoscopic Cholecystectomy for Benign Gallbladder Diseases: A Systematic Review and Meta-Analysis. Surgical Endoscopy, 32, 4377-4392. https://doi.org/10.1007/s00464-018-6295-9

  29. NOTES

    *通讯作者。

期刊菜单